Full Breakdown
Summit Therapeutics Faces Setback with Ivonescimab in Lung Cancer Trials
9/9/2025, 11:16:49 PM
Overview of the Clinical Trial Results
Summit Therapeutics Inc. experienced a significant decline in its stock value following the release of disappointing results from its Phase III HARMONi trial for ivonescimab, an experimental drug for advanced lung cancer. The trial, which tested ivonescimab in combination with chemotherapy, failed to demonstrate a statistically significant improvement in overall survival compared to chemotherapy alone. While the combination showed promise in terms of progression-free survival, the overall survival data did not meet the necessary benchmarks for FDA approval.
Key Findings from the HARMONi Trial
The HARMONi trial results indicated that patients receiving ivonescimab lived a median of 17 months, compared to 14 months for those on chemotherapy alone. However, the overall survival hazard ratio of 0.78, while suggesting an improvement, did not achieve statistical significance. Analysts noted that the subgroup data from North American and European patients raised concerns about the drug's efficacy, with discrepancies making the results "uninterpretable." As a result, Summit's stock plummeted by 25.2% to $19.44.
Implications for FDA Approval and Market Position
The failure to demonstrate a clear overall survival benefit raises doubts about the likelihood of FDA approval for ivonescimab. Leerink Partners analyst Daina Graybosch expressed skepticism, stating, "We believe it is unlikely FDA will grant approval based on the study called HARMONi." This sentiment was echoed by other analysts who suggested that the mixed results could hinder Summit's ability to secure a marketing partner at the expected valuation of over $15 billion.
Safety Profile and Comparisons
Despite the disappointing survival data, the safety profile of ivonescimab appeared manageable. The trial reported that 3% of patients on ivonescimab discontinued treatment due to side effects, compared to 5% in the chemotherapy group. Treatment-related deaths were reported in 1.8% of ivonescimab patients versus 2.3% in the chemotherapy group. However, analysts like Graybosch recommended considering alternatives, such as BioNTech, which is more diversified and partnered with Bristol Myers Squibb.
Criticism and Opposition
Critics have pointed out that the results from the HARMONi trial do not align with earlier findings from studies conducted in China, where ivonescimab showed a statistically significant benefit in survival. The fragmented data from different geographical regions has led to skepticism about the drug's potential as a competitor to established therapies like Merck's Keytruda.
Future Outlook
Summit executives have indicated plans to finalize a strategy for filing for U.S. approval, despite the challenges posed by the recent trial results. They acknowledged the timing of the survival readouts and the conflicting findings as potential hurdles. Analysts suggest that it may be more prudent for Summit to wait for additional data from ongoing trials before pursuing FDA negotiations.
Verbatim Quotes
- “We believe it is unlikely FDA will grant approval based on (the study called) HARMONi nor that Summit will partner ivo at the substantial valuation expected by investors — greater than $15 billion with more than half up front,” — Daina Graybosch, Analyst at Leerink Partners
- “The details on the Asian vs. non-Asian subgroups were worse than we expected,” — Piper Sandler & Co Analysts
- “Some of the conversations I've had just in the last few hours are with people who have actually used ivonescimab, who are extremely committed to it, who have participated in this trial,” — Jack West, VP of Clinical Development at Summit
In summary, Summit Therapeutics faces significant challenges following the HARMONi trial results, which have cast doubt on the viability of ivonescimab as a treatment for lung cancer and its potential for FDA approval.
